

1                    **Comparative Analysis of Nebulizers in Clinical use for**  
2                    **Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)**

3  
4                    Short title: Technical characterisation of PIPAC nebulizers

5  
6                    Daniel Göhler, Dipl.-Ing.<sup>1,2</sup>, Kathrin Oelschlägel, Dipl.-Ing<sup>1</sup>, Mehdi Ouaiissi, Prof, MD,  
7                    PhD<sup>3,4</sup>, Urs Giger-Pabst, Prof, MD<sup>3,5</sup>

8  
9                    <sup>1</sup> Topas GmbH, Dresden, Germany

10                    <sup>2</sup> Research Group Mechanical Process Engineering, Institute of Process Engineering and  
11                    Environmental Technology, Technische Universität Dresden, Dresden, Germany

12                    <sup>3</sup> EA4245 Transplantation, Immunology, Inflammation, Université de Tours, France

13                    <sup>4</sup> Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver  
14                    Transplant Surgery, University Hospital of Tours, France

15                    <sup>5</sup> Fliedner Fachhochschule, University of Applied Science Düsseldorf, Düsseldorf, Germany

16  
17  
18                    **Corresponding author:**

19                    Urs Giger-Pabst, MD

20                    University of Applied Science

21                    Fliedner Fachhochschule

22                    Geschwister-Aufricht-Straße 9

23                    40489 Düsseldorf, Germany

24                    E-Mail: [ursgiger@gmx.net](mailto:ursgiger@gmx.net)

25                    Phone: +49 163 729 44 07

26  
27  
28                    **Key words**

29                    Pressurized Intraperitoneal Aerosol Chemotherapy, PIPAC, aerosol droplet size, gravimetry,

30                    Nebulizer, MCR-4 Topol<sup>®</sup>, HurriChem<sup>™</sup>, QuattroJet

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 **Author Contributions**

33 Daniel Göhler and Urs Giger-Pabst: study design, experiments, data acquisition, data  
34 interpretation and drafting of manuscript.

35 Kathrin Oelschlägel and Mehdi Ouaiissi: critical revision for important intellectual content of  
36 the manuscript according to their field of research.

37 **Disclosure**

38 Strictly academic study supported by institutional funds. All authors have no conflicts of  
39 interest or financial ties to declare.

40 **Data Availability Statement**

41 All relevant data are within the manuscript. Raw data will be provided by the corresponding  
42 author upon request.

43 **Legal background**

44 Purely technical analyses without the use of biological material or patients requiring no specific  
45 legal authorization or ethics vote.

46 **Acknowledgments**

47 The authors thank Professor Marc Pocard, Hepato-Biliary-Pancreatic Gastrointestinal Surgery  
48 and Liver Transplantation, Pitié Salpêtrière Hospital, AP-HP, F-75013 Paris, France, for  
49 providing a HurriChem™ (ThermaSolutions, White Bear Lake, MN, USA) nozzle.

50

51 **Abstract**

52 *Objective:* Technical ex-vivo comparison of commercial nebulizer nozzles used for Pressurized  
53 Intraperitoneal Aerosol Chemotherapy (PIPAC).

54 *Methods:* The performance of four different commercial nebulizer nozzles (Nebulizer;  
55 HurriChem™; MCR-4 TOPOL®; QuattroJet) was analysed by comparing: i) technical design  
56 and principle of operation, ii) operational pressure as function of the liquid flow rate, iii) droplet  
57 size distribution via laser diffraction spectrometry, iv) spray cone angle, spray cone form, and  
58 horizontal drug deposition through image-metric analyses, and v) chemical resistance via  
59 exposing to a cytostatic solution and metallurgic composition by means of spark optical  
60 emission spectral analysis.

61 *Results:* The Nebulizer exhibits a nearly identical technical design, implying a comparable  
62 performance (e.g., mass median droplet size of 29 µm) as the original PIPAC nozzles (MIP/  
63 CapnoPen). The other three nozzles demonstrate varying degrees of performance deviation  
64 from the original PIPAC nozzles. The HurriChem™ shares a similar design and principle of  
65 operation as the Nebulizer, but produces a finer aerosol with a particle size of 22 µm. The  
66 operating principles of MCR-4 TOPOL® and QuattroJet significantly differ from that of the  
67 original PIPAC nozzle technology. The MCR-4 TOPOL® nebulizer has a hollow spray cone  
68 that leads to the production of significantly larger aerosol droplets (50 µm) compared to the  
69 original PIPAC nozzles. The QuattroJet generates an aerosol droplet (22 µm) similar in size to  
70 the HurriChem™ and exhibits improved spatial drug distribution.

71 *Conclusion:* While the introduction of new PIPAC nozzles is a welcome development,  
72 differences in performance and efficacy were noted. Therefore, it is recommended that PIPAC  
73 nozzles that deviate from the current standard undergo bioequivalence testing and be  
74 implemented in accordance with the IDEAL-D framework prior to routine clinical use.

75

76 **1 Introduction**

77 More than a decade ago, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) was  
78 introduced clinically as a new approach to deliver intraperitoneal chemotherapy to patients  
79 suffering from end-stage peritoneal surface malignancies. Using a high-pressure injector  
80 connected to a specially designed PIPAC nozzle, liquid chemotherapeutic drugs are aerosolised  
81 during laparoscopic surgery within the capnoperitoneum. This approach is expected to have a  
82 better spatial drug distribution pattern, greater depth of tissue penetration, and higher drug  
83 concentration in the tissue than conventional liquid intraperitoneal chemotherapy [1, 2].  
84 Clinical data from phase I/II and larger mono- and multicentre case series regarding safety,  
85 feasibility, and oncologic efficacy are encouraging. While the therapeutic role of PIPAC  
86 remains uncertain [3], there are ongoing prospective randomized PIPAC trials, and their results  
87 are eagerly awaited [4, 5].

88 Until recently, the original PIPAC nozzle was the only option available for clinical use. More  
89 than 18`000 documented clinical applications worldwide were recorded by the end of 2022 [3].  
90 Significant efforts have been dedicated to standardizing PIPAC therapy globally in order to  
91 compare efficacy. [6, 7]. Technical and clinical performance of the original PIPAC nozzle have  
92 been extensively studied in pre- and clinical settings [3, 8, 9]. The recent introduction of new  
93 nebulizer devices and their clinical use requires a detailed evaluation of their physical  
94 properties. As of now, very limited comparative data are available for the newly introduced  
95 PIPAC nozzles. Oncological surgeons are now confronted with the question of whether these  
96 newer nozzles are equivalent to the original nozzle technology or if they possess potential  
97 technical or functional advantages or disadvantages that could impact oncological outcomes.

98 Building upon the methodological findings regarding the technical characterization of the  
99 original PIPAC nozzle [8], the present study focuses on the comparative performance  
100 characterization of four commercially available nebulizers commonly used in PIPAC  
101 procedures.

102

103

104

105

## 106 **2 Materials and Methods**

### 107 **2.1 Examined PIPAC nozzles**

108 Four commercial single-substance PIPAC nozzles for intraperitoneal drug aerosolization were  
109 examined, i.e.,

- 110 • Nebulizer, Model 770-12, REGER Medizintechnik, Villingendorf, Germany (A),
- 111 • HurriChem™, ThermaSolutions, White Bear Lake, MN, United States of America (B),
- 112 • MCR-4 TOPOL®, SKALA-Medica, Soběslav, Czech Republic (C),
- 113 • QuattroJet, Model 770-14, REGER Medizintechnik, Villingendorf, Germany (D).

114 After the experiments, all nozzles were longitudinally cut open in the middle at a 180° angle  
115 using a computerized numerical control milling machine to investigate their principles of  
116 operation. In addition, also the dimensions of the nozzle outlet orifices were examined by light  
117 microscopy (SMZ1500, Nikon, Tokyo, Japan).

### 118 **2.2 Barometric characterisation of operational pressure as function of liquid flow rate**

119 To characterise the operational pressure over the volumetric liquid flow rate, the nozzles were  
120 connected via high-pressure hose lines with a high-pressure injector (ACCUTRON® HP-D,  
121 MEDTRON AG, Saarbrücken, Germany) to push the test liquid (Glucosterile 5%, Fresenius  
122 Kabi GmbH, Germany) through the nozzles. The operational pressure induced by the liquid  
123 flow rate was determined by means of a glycerine-filled bourdon gauge (MA7U-25, JRA  
124 Maschinenteile und Geräte GmbH, Reichenbach, Germany), which was implemented in the  
125 high-pressure line. For the analyses, the volumetric liquid flow rate was increased stepwise  
126 either by 0.1 ml/s (for nozzles A, B and D) or by 0.2 ml/s (for nozzle C) until the maximum  
127 permitted pressure of 21 bar of the high-pressure injector was reached. For nozzle D, only the  
128 axial nozzle was tested - the horizontal nozzles were sealed watertight. Analogous to [8],  
129 measurement values were taken at steady state conditions of the aerosolization process, and all  
130 analyses were repeated three times.

### 131 **2.3 Granulometric characterisation of droplet size distributions**

132 The droplet size distributions of the aerosols generated from the test liquid (Glucosterile 5%,  
133 Fresenius Kabi GmbH, Germany) were characterised by laser diffraction spectrometry  
134 (PW180-C spray particle size analyser, Jinan K-Ring Technology Co., Ltd, Shandong, China)

135 over a size range of (0.57 - 780)  $\mu\text{m}$ . The outlets of the PIPAC nozzles were arranged via a  
136 tripod in a distance of 5 mm perpendicular to the centre of the free-accessible red laser beam.  
137 To characterise the aerosolization performance, all analyses were performed contemporaneous  
138 with the barometric characterisation of the operational pressure for various liquid flow rates.  
139 Analogous to [8], measurement values were taken at steady state conditions of the  
140 aerosolization process and all analyses were repeated three times.

#### 141 ***2.4 Image-metric characterisation of spray cone angles, form and horizontal drug*** 142 ***deposition areas***

143 The spray cone angles, the form of the spray cones and the horizontal drug deposition area were  
144 characterised with different test liquids at nozzle-specific operation conditions as recommended  
145 by the manufacturers, i.e., at a volumetric liquid flow rate of 0.5 ml/s for the nozzles A, B, at  
146 2.0 ml/s for nozzle C and 1.5 ml/s for nozzle D. The former two characteristics were evaluated  
147 on the base of a 5 wt.-% aqueous glucose solution (Glucosterile 5%, Fresenius Kabi GmbH,  
148 Germany), while the latter characteristic was assessed by operating the nozzles with undiluted  
149 royal blue ink (Pelikan Tinte 4001<sup>®</sup>, Hannover, Germany).

150 For the spray cone angle analyses, the nozzles were fixed on a tripod and vertically aligned.  
151 Photographic images were taken with a camera that was perpendicular positioned to the nozzle  
152 direction. The images were in-silico processed by overlaying with a digital 360° full-circle  
153 protractor for determining the spray cone angles.

154 The form of the spray cones was visualized by means of a line laser (GCL 2-15, Robert Bosch  
155 Power Tools GmbH, Leinfelden-Echterdingen, Germany) positioned in distance of 60 mm from  
156 the nozzle orifice at right angle into the spray cone. Fully evaluated spray cone forms were  
157 finally documented photographically.

158 The horizontal drug deposition on a level-aligned blotting paper was examined by operating the  
159 vertically aligned nozzles with a distance of 60 mm between the blotting paper and the nozzle  
160 orifice. The blotting paper was exposed for 3 s to the fully-developed spray jet. To achieve this,  
161 a mechanical diaphragm was placed in front of the spray jet. The diaphragm was opened  
162 automatically within 0.1 s, when the aerosol jet showed steady state nebulisation condition.

163

164

165 **2.5 *Assessing of chemical resistance and chemical composition***

166 To assess the chemical resistance of the nozzle material against chemotherapeutic drugs, the  
167 nozzles were at first exposed to a cytostatic solution for 12 hours and afterwards stored in the  
168 dark at room temperature for 12 days within petri dishes. The chosen cytostatic solution was  
169 prepared in accordance to the mixture of high pressure/high dose PIPAC (HP/HD-PIPAC) [10],  
170 i.e., 6 mg of doxorubicin (Accord 2 mg/ml, Accord Healthcare GmbH, Munich, Germany) was  
171 admixed to a total volume of 50 ml with a 0.9 wt.-% aqueous sodium chloride solution (Ecolav®  
172 100, B. Braun, Melsungen, Germany). Finally, the nozzles were milled open in a laminar flow  
173 workbench and macroscopic changes were documented photographically.


174 Furthermore, the chemical composition of the nozzles pipes was characterised for the following  
175 elements: C, Si, Mn, P, S, Cr, Ni, Mo, Cu, W and N by means of spark optical emission spectral  
176 analysis (SPECTROMAXx, SPECTRO Analytical Instruments GmbH, Kleve, Germany) via  
177 an independent, state-recognized laboratory (WS Material Service GmbH, Essen, Germany).

178

179 **3 Results**

180 **3.1 *Technical design and principle of operation***

181 The 90° sectional views of the head regions in Figure 1 show technical details of the examined  
182 nozzles.



183

184 **Figure 1:** 90° sectional views of the head regions of the nozzles. Legend: O = outlet orifice; H = nozzle  
185 head; I = bar inlay with distal transverse borehole; M = double metal grid; N = fixed needle; S = shaft;  
186 T = twist body.

187 Externally, all nozzles consist of a stainless steel shaft (S) with a more or less pronounced nozzle  
188 head (H) on the lower part and a Luer lock thread on the upper part (not shown in Figure 1).  
189 The Luer lock threads serve for the connection of the nozzles with high-pressure injectors via  
190 high-pressure hose lines. Internally, the nozzles show considerable differences (Figure 1). It is  
191 worth noting that nozzle A and B exhibit a nearly identical construction and principle of  
192 operation. However, both nozzle C and D differ significantly from each other and from nozzle  
193 A and B


194 In the case of the nozzles A, B and D, the liquid drug is supplied internally from the Luer lock  
195 connector to the nozzle head via an annular gap between the outer shaft (S) and a bar inlay with  
196 distal transverse borehole (I). In contrast, the internal liquid drug supply of nozzle C occurs  
197 directly via the hollow cavity of the shaft (S). Moreover, nozzle C is equipped with a double  
198 metal grid (M) with two different mesh sizes that serve as particle filter.

199 While the nozzles A and B contain one twist body (T), nozzle D is equipped with four twist  
200 bodies (i.e., with one axial and three lateral twist bodies in 120° arrangement) to improve the  
201 spatial drug distribution within the abdominal cavity. The twist bodies (T) of the nozzles A, B



202 and D contain longitudinally superficially milled grooves at 180° intervals. As the liquid drug  
203 flow rate passes along the twist bodies (T) they were set into rotation that improves the  
204 aerosolisation prior leaving the nozzle via the outlet orifice (O). In the case of nozzle C, the  
205 twist body is replaced by an fixed metal needle (N). This needle contains also laterally located,  
206 spirally milled axial grooves that induce a whirlwind effect for aerosolisation when passed by  
207 the liquid flow before leaving the nozzle via the outlet orifice (O).

208 Light microscopic images of the outlet orifices (O) with determined orifice diameters of the  
209 examined nozzles are shown in Figure 2.




211 **Figure 2:** Light microscopic images of the outlet orifices with determined orifice diameters of the  
212 examined nozzles; scaling in mm. Nozzles A, B, C, D

### 213 3.2 Operational parameters based on barometric and granulometric analyses

214 In Figure 3a, the operational pressure of the examined nozzles is shown as a function of the  
215 liquid flow rate. Figure 3b displays the mass median diameter of the droplet size distribution  
216 over the operational pressure. To avoid artefacts due clouding of the optics of the laser  
217 diffraction spectrometer, the lateral nozzles of nozzle D (QuattroJet) were taped off for the  
218 granulometric analyses and a flow rate of 0.5 ml/s was chosen (manufacturer-recommended  
219 flow rate of 1.5 ml/s) Note that the shown data are determined at steady state conditions of the  
220 aerosolization process analogous to [8]. Figure 3a shows that the determined operational  
221 pressure data for all examined nozzles fit well with the fluid dynamic theory, i.e., the dynamic  
222 pressure (or the dynamic pressure drop) of an incompressible fluid increases with the fluid  
223 velocity by the power of two. According to the equation of continuity, the fluid velocity of an  
224 incompressible fluid is in turn directly proportional to the volumetric liquid flow rate. The  
225 nozzles A, B and D show a similar performance regarding operational pressure and liquid flow  
226 rate, while nozzle C (MCR-4 TOPOL<sup>®</sup>) has a significantly lower pressure drop, and thus, a  
227 considerable higher volumetric liquid flow rate at a specific operational pressure.

228 In addition to the entire operational spectrum, the study also separately investigated the  
 229 manufacturer-recommended operational conditions, i.e., at a volumetric liquid flow rate of  
 230 0.5 ml/s for nozzle A (Nebulizer) and nozzle B (HurriChem™), 1.3 - 2.0 ml/s for nozzle C  
 231 (MCR-4 TOPOL®) and 1.5 ml/s for nozzle D (QuattroJet). Under these conditions nozzle C  
 232 showed with (18 - 26) s the shortest initiation time to reach the corresponding steady state  
 233 pressure of (7.4 - 18.1) bar, followed by nozzle A with 52 s (15.7 bar) and nozzle D with 94 s  
 234 (16.0 bar). Note that with taped-off lateral nozzles, nozzle D shows a higher operational  
 235 pressure of 19.3 bar (as shown in Figure 3).



236

237 **Figure 3:** Operational pressure as function of the liquid flow rate from barometric analyses (a), mass

238 median diameter as function of the operational pressure from granulometric analyses (b) and volume-


239 weighted distributions density (c) and cumulative distribution (d) of droplets at certain manufacturer-  
240 recommended operational condition; black cycles/ellipses indicate manufacturer-recommended  
241 operation condition.

242 Figure 3b shows that the mass median diameter of the generated droplet aerosols depends for  
243 each nozzle significantly on the operational pressure. With increasing operational pressure, the  
244 mass median diameter decreases. For operational pressures of  $\leq 4$  bar, no significant differences  
245 between the different nozzles were observed. This is attributed to a non-fully developed  
246 aerosolization of the supplied liquid. For operation pressures of  $\geq 5$  bar stable aerosol generation  
247 is reached and differences between the nozzles can be observed. For operational pressures  $\geq 5$   
248 bar, nozzle C (MCR-4 TOPOL<sup>®</sup>) shows the coarsest mass median diameters, followed by  
249 nozzle A (Nebulizer). The finest mass median diameters were determined for nozzle B  
250 (HurriChem<sup>™</sup>) and D (QuattroJet).

251 The same ranking can also be deduced by the volume-weighted droplet size distributions of the  
252 aerosols as generated by the nozzles at the manufacturer-recommended operation conditions  
253 (Figure 3c, Figure 3d). Moreover, it can be observed in Figure 3c and Figure 3d, that each  
254 aerosol has a polydisperse and bimodal droplet size distribution.

### 255 **3.3 Operational parameters based on image-metric analyses**

256 Figure 4 shows photographic images for the spray cone angle (upper panel), the spray cone  
257 form (mid panel) and the horizontal drug deposition area (lower panel) of each examined nozzle  
258 as determined at manufacturer-recommended operational conditions.



259


260 **Figure 4:** Photographic images of spray cone angle (upper panel), of spray cone form (middle panel)  
261 and horizontal drug deposition area (lower panel, scale in cm). Nozzles A, B, C, D.

262 According to the upper panels of Figure 4, the widest single spray cone angle, 79°, was achieved  
263 with nozzle C (MCR-4 TOPOL®), 72° for nozzle A (Nebulizer), 71° for nozzle B  
264 (HurriChem™), and 67° for nozzle D (QuattroJet). While Nozzle D exhibits the smallest single  
265 spray cone angle (67°), it should be noted that unlike the other nozzles, Nozzle D consists of  
266 four spray cones. As shown in the middle panels of Figure 4, nozzle A (Nebulizer), nozzle B  
267 (HurriChem™) and nozzle D (QuattroJet) generate a full spray cone, whereas nozzle C (MCR-  
268 4 TOPOL®) produces a hollow spray cone. The full spray cones of the nozzles A, B and C lead  
269 to completely filled circular areas of horizontal drug deposition beneath the nozzles as shown  
270 in the lower panel of Figure 4. In the case of the nozzles A and B, a circular deposition area of  
271 approx. 38.5 cm<sup>2</sup> (outer diameter of approx. 7 cm) was determined. The lateral outlets of nozzle  
272 D showed in addition to the axial circle (outer diameter of approx. 7 cm) 3 additional deposition

273 areas of (13 × 20) cm that accumulate to an overall horizontal deposition area of approx.  
274 679 cm<sup>2</sup>.

### 275 3.5 Chemical resistance and chemical composition

276 Photographic images of the nozzle parts after prolonged exposure to the cytostatic solution are  
277 shown in Figure 5.



278  
279 **Figure 5:** Photographic images of the nozzle parts after exposure to the cytostatic solution. Nozzle A,  
280 B, C, D.

281 As shown in Figure 5, no macroscopic corrosion was observed except for nozzle C (MCR-4  
282 TOPOL<sup>®</sup>). Prolonged exposure to cytostatic solution led to the formation of iron oxide.  
283 Corrosion was particularly pronounced on the fine-mesh particle filter, the nozzle needle, and  
284 the nozzle head housing. No changes were observed for the nozzles A, B and D either visually  
285 or by light microscopic analyses.

286 Analysis of chemical composition revealed that nozzles A, B and D fulfil requirements of  
287 stainless steel 1.4301, typically used for surgical instruments according to EN 10088-3:2014  
288 [11]. Nozzle C (MCR-4 TOPOL<sup>®</sup>) showed a twelve times higher quantity of sulphur  
289 (0.012 wt.-% vs. 0.001wt.-%). In addition, molybdenum (0.183 wt.-%), copper (0.220 wt.-%)  
290 and tungsten (0.134wt.-%) were identified by spark optical emission spectrometry for nozzle  
291 C.

292

## 293 4 Discussion

294 Given the current lack of knowledge, this study conducted a comparative performance analysis  
295 of four clinically used nebulizing nozzles for PIPAC. The key technical characteristics of these  
296 nozzles are summarised in Table 1.

297 **Table 1:** Overview on technical and functional characteristics of the examined nozzles; \* =  
298 manufacturer-recommended operational conditions.

parameter	unit	A (Nebulizer)	B (HurriChem™)	C (MCR-4 TOPOL®)	D (QuattroJet)
*liquid flow rate (*Q <sub>L</sub> )	ml/s	0.5	0.5	1.3 - 2.0	1.5
operational pressure for *Q <sub>L</sub>	bar	15.7	14.9	7.4 – 18.1	16.0
pressure initiation time for *Q <sub>L</sub>	s	52	100	18 - 26	94
nozzle orifice diameter	µm	200	190	370	170
mass median diameter for 15 bar	µm	28.95	20.99	52.17	24.18
max. spray angle for *Q <sub>L</sub>	°	≈ 72	≈ 71	≈ 79	≈ 67
number of nozzles	-	1 × axial	1 × axial	1 × axial	1 × axial, 3 × lateral
kind of spray cone	-	full cone	full cone	hollow cone	full cone
drug deposition area for *Q <sub>L</sub>	cm <sup>2</sup>	≈ 38.5	≈ 38.5	≈ 66	≈ 679

299  
300 Nozzle A (Nebulizer) shows after an initiation time of 52 s an operational pressure of 15.7 bar  
301 at the manufacturer-recommended operational liquid flow rate of 0.5 ml/s. Thereby, a full spray  
302 jet cone (71°) composed of droplets with a mass median diameter of 29 µm is formed. The data  
303 of this study reveal that nozzle A is identical in design and performance to the nozzle type that  
304 was already introduced 10 years ago for clinical use (microinjection pump (MIP)) [8], which  
305 was also distributed under the tradename CapnoPen.

306 Nozzle B (HurriChem™) is another nebulizer that has recently been introduced for PIPAC use.  
307 Examinations on design and principle of operation show a high similarity with nozzle A  
308 (Nebulizer) and thus also with the initial PIPAC nozzle technology. At the manufacturer-  
309 recommended operational liquid flow rate of 0.5 ml/s, nozzle B shows after an initiation time  
310 of 100 s an operational pressure of 14.9 bar. The mass median diameter of the droplets in the  
311 formed full spray jet cone (73°) was determined to be 21 µm.

312 Nozzle C (MCR-4 TOPOL®) differs from other nozzles investigated in terms of technical  
313 design, principle of operation, operational parameters, and aerosol characteristics. The  
314 operation of nozzle C is accompanied by the formation of a hollow spray cone jet (79°). At the  
315 manufacturer-recommended operational liquid flow rate range of (1.3 - 2.0) ml/s, operational  
316 pressures of (7.4 - 18.1) bar were reached rapidly (18 - 26) s. The mass median droplet size  
317 decreases with increasing liquid flow rate but was found to be in each case larger than 50 µm.

318 Nozzle D (QuattroJet) is a further PIPAC nebulizing nozzle that was introduced by the same  
319 manufacturer as for nozzle A. To optimize the spatial drug distribution pattern and achieve

320 higher intraabdominal aerosol particle concentration, the conventional axial nozzle is  
321 supplemented in nozzle D by three further nozzles, which are arranged lateral at the nozzle head  
322 with an angular distance of 120°. Nozzle D is based on the same technology as nozzle A. At  
323 the manufacturer-recommended flow rate of 1.5 ml/s, nozzle D shows an operational pressure  
324 of 16.0 bar after an initiation time of 92 s and provides four full spray cone jets (67°) composed  
325 of droplets with a mass median diameter of 21 µm.

326 Recently, a first attempt regarding recommendations on the minimum technical requirements  
327 on nozzles suitable for PIPAC treatment was published. A minimum requirement for the spray  
328 angle of at least 70° was defined [12] by implying that the spray cone angle corresponds to the  
329 achievable drug deposition area. In this study we found that not all nozzles fulfil this  
330 requirement. The requirement is matched by nozzles A, B and C. Nozzle D achieves a slightly  
331 lower spray cone angle (67°) than required, however the four spatially-displaced spray jets  
332 achieve a total spray angle of 268°. Nozzle C, unlike all other nozzles examined, produces a  
333 hollow spray cone, resulting in a ring-shaped drug deposition area that was smaller than that of  
334 a full spray cone jet at the same spray cone angle. Regarding nozzle performance, the drug  
335 deposition area seems to be an even better technical parameter than the spray cone angle.

336 The nozzles C (MCR-4 TOPOL®) and D (QuattroJet) investigated in this study, in contrast to  
337 A (Nebuliser) and B (HurriChem™), and thus in contrast to the primary PIPAC nozzle  
338 technology, show significant differences in their operating principle and performance. Nozzle  
339 C offers the largest spray cone angle of all examined nozzles, but produces a hollow spray cone.  
340 It is not known if such a spray jet improves drug distribution and drug penetration, since no  
341 preclinical studies exist comparing a hollow with a full spray cone. Nozzle D provides multiple  
342 spray cones that can significantly improve the spatial drug distribution by reduction of high  
343 local deposition and thus high local tissue toxicity. Nonetheless, these potential benefits of  
344 multi-nozzle systems need to be confirmed by further research.

345 In contrast to the other nozzles, nozzle C (MCR-4 TOPOL®) exhibits a macroscopically visible  
346 formation of iron oxide after long-term exposure to a cytostatic solution containing sodium  
347 chloride. Based on spark optical emission spectrometry, it was discovered that nozzle C was  
348 made from steel with a significantly higher sulphur content (0.012 wt.-% vs. 0.001 wt.-%),  
349 along with contamination of molybdenum (0.183 wt.-%), copper (0.220 wt.-%), and tungsten  
350 (0.134 wt.-%). Short-term exposure of the nebulizers to cytostatic solution reveals no

351 immediate macroscopic corrosion. Nevertheless, it is not possible to completely rule out a  
352 potential risk to the patient.

353 Currently, there are only limited preclinical data to suggest that there is an optimal technique  
354 for the generation and delivery of PIPAC aerosols that could improve clinical outcome.  
355 However, it is clear that, contrary to claims made by one manufacturer [13], larger aerosol  
356 droplets injected into the peritoneal cavity at higher velocities with a hollow spray cone do  
357 neither improve the spatial distribution pattern [8, 14] nor tissue penetration depth per se.  
358 Nebulizers differing from the present standard technology in design, especially in spraying  
359 characteristics, cannot automatically be considered equivalent by the clinical user. Therefore,  
360 before their broad clinical use, the individual innovation phases should be systematically tested,  
361 ideally following the recommendation of the IDEAL-D framework for the introduction of  
362 medical devices [15, 16]. While the original nozzle technology has completed phase I - IIb [17]  
363 and phase III trials are ongoing [4, 5], only limited phase I clinical user data has been published  
364 for nozzle C (MCR-4 Topol®) [18] and such data are lacking for nozzle B and D.

365 In the near future, clinical users should have the assurance that technical testing and reporting  
366 adhere to scientific standards and widely accepted global standards, including ISO standards.  
367 For PIPAC nebulizers, such standards should ideally be set by a panel of experts. Moreover,  
368 nebulizers with significant technical and granulometric differences from the standard  
369 technology should undergo first ex- and in-vivo animal testing before clinical use.  
370 Manufacturers should be obliged to have the bioequivalence of the cytostatic drugs  
371 administered independently certified in comparison to standard nebulizer systems, analogous  
372 to drugs and their generics. Relevant outcome measures are aerosol characteristics, spatial drug  
373 distribution, depth of penetration, tissue concentration and the peak concentration and the area  
374 under the curve describing the extent of peritoneal passage [8, 19 - 28]. The ratio between the  
375 individual properties of the generic nebulizer and the reference product would ideally be 1:1 in  
376 case of bioequivalence. As this is unlikely to be achieved, the US Food and Drug  
377 Administration (FDA), for example, requires the 90% confidence interval for drugs and their  
378 generics to be between 0.80 and 1.25 [29]. Similar to such FDA specifications, new PIPAC  
379 nozzle technologies could be tested comparatively in the future. Such preclinical testing, ideally  
380 using standardized models, could prevent the use of devices compromising clinical outcomes  
381 and/or harming healthcare professionals/patients. Finally, it would be helpful for the



382 comparability of clinical results if the nebulizer type used in each case will be also recorded in  
383 the PIPAC database (<https://isspp.org/professionals/pipac-database/>).

384

## 385 **5 Conclusion**

386 Four clinically-used nozzles to aerosolise chemotherapeutic drugs in the context of Pressurized  
387 Intraperitoneal Aerosol Chemotherapy (PIPAC), i.e., the Nebulizer, the HurriChem<sup>TM</sup>, the  
388 MCR-4 TOPOL<sup>®</sup> and the QuattroJet were comparatively examined to determine their  
389 performance.

390 We confirmed that the Nebulizer exhibits a nearly identical technical design, and thus similar  
391 performance to the original PIPAC nozzles MIP/CapnoPen. The PIPAC nozzle HurriChem<sup>TM</sup>  
392 is based on a similar technical design as the Nebulizer nozzle but provides a finer aerosol due  
393 to a smaller nozzle orifice opening. Both, the MCR-4 TOPOL<sup>®</sup> and the QuattroJet deviate in  
394 the principles of design and operations from the Nebulizer, and thus, the original PIPAC  
395 technology. While the MCR-4 TOPOL<sup>®</sup> provides the coarsest aerosol of the four nozzles  
396 examined, the QuattroJet delivers an aerosol similar to that of the HurriChem<sup>TM</sup>. In contrast to  
397 the HurriChem<sup>TM</sup>, the QuattroJet comes with the feature of four spray cones (one axial, three  
398 lateral) to improve the spatial drug distribution and a higher aerosol particle number  
399 concentration.

400 The availability of new PIPAC nozzles with unique features is encouraging but can also  
401 negatively impact optimization and standardization of PIPAC protocols for the treatment of  
402 peritoneal carcinomatosis. It is therefore recommended that nozzles for which the  
403 technical/granulometric characteristics differ from the current standard technology must be  
404 subjected to preclinical proof of equivalence in terms of spatial drug distribution, tissue  
405 penetration and concentration before routine clinical use. New nebulizers should be investigated  
406 and introduced for clinical use in accordance with the IDEAL-D framework.

407

## 408 **References**

- 409 1. Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA Description of a novel  
410 approach for intraperitoneal drug delivery and the related device. *Surg. Endosc.*  
411 2012;26(7):1849–1855. Doi: 10.1007/s00464-012-2148-0.
- 412 2. Solaß W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal  
413 carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence  
414 for efficacy. *Ann. Surg. Oncol.* 2014;21(2):553–559. Doi: 10.1245/s10434-013-3213-1.
- 415 3. Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy:  
416 rationale, evidence, and potential indications. *Lancet Oncol.* 2019;20(7):e368–e377. Doi:  
417 10.1016/S1470-2045(19)30318-3
- 418 4. Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC Pressurized IntraPeritoneal Aerosol  
419 Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases  
420 secondary to platinum resistant ovarian cancer – study protocol for a randomized control  
421 trial. *Pleura and Peritoneum* 2019;4(1). Doi: 10.1515/pp-2018-0111
- 422 5. Casella F, Bencivenga M, Rosati R, et al. Pressurized intraperitoneal aerosol chemotherapy  
423 (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer:  
424 a randomized multicenter phase III trial PIPAC VEROne. *Pleura and Peritoneum*  
425 2022;7(3):135–141. Doi: 10.1515/pp-2022-0111
- 426 6. Sgarbura O, Villeneuve L, Alyami M, et al. Current practice of pressurized intraperitoneal  
427 aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?  
428 *European Journal of Surgical Oncology* 2021;47(1):149–156. Doi:  
429 10.1016/j.ejso.2020.08.020
- 430 7. Sgarbura O, Eveno C, Alyami M, et al. Consensus statement for treatment protocols in  
431 pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Pleura and Peritoneum*  
432 2022;7(1):1–7. Doi: 10.1515/pp-2022-0102
- 433 8. Göhler D, Khosrawipour V, Khosrawipour T, et al. Technical description of the micro  
434 injection pump (MIP®) and granulometric characterization of the aerosol applied for  
435 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). *Surg. Endosc.*  
436 2017;31(4):1778–1784. Doi: 10.1007/s00464-016-5174-5
- 437 9. Nadiradze G, Horvath P, Sautkin Y, et al. Overcoming Drug Resistance by Taking  
438 Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy  
439 (PIPAC). *Cancers* 2020;12(1):34. Doi: 10.3390/cancers12010034.

- 440 10. Arias GR, Sindayigaya R, OuaiSSI M, et al. Safety and Feasibility of High-Pressure/High-  
441 Dose Pressurized Intraperitoneal Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and  
442 Metastatic Peritoneal Surface Malignancies. *Ann. Surg. Oncol.* 2022. Doi: 10.1245/s10434-  
443 022-12698-4.
- 444 11. EN 10088-3:2014. Stainless steels - Part 3: Technical delivery conditions for semi-finished  
445 products, bars, rods, wire, sections and bright products of corrosion resisting steels for  
446 general purpose.
- 447 12. Pocard M, So JBY, Huchon C, et al. PIPAC nebulizer: How to test the new devices in the  
448 market, expert recommendations. *Journal of Visceral Surgery* 2022. Doi:  
449 10.1016/j.jviscsurg.2022.10.001.
- 450 13. PIPAC – Pressurized Intraperitoneal Aerosol Chemotherapy; [https://www.skala.cz/en/mcr-  
451 4-topol-en/](https://www.skala.cz/en/mcr-4-topol-en/) (access: 5<sup>th</sup> March 2023 at 11:02 CET)
- 452 14. Hinds, William C. (1999). *Aerosol technology: properties, behaviour, and measurement of  
453 airborne particles*. New York: Wiley. ISBN 978-0-471-19410-1.
- 454 15. Sedrakyan A, Campbell B, Merino JG, Kuntz R, Hirst A, McCulloch P IDEAL-D: a rational  
455 framework for evaluating and regulating the use of medical devices. *Br. Med. J.* 2016;i2372.  
456 Doi: 10.1136/bmj.i2372.
- 457 16. Páez A, Rovers M, Hutchison K, Rogers W, Vasey B, McCulloch P Beyond the RCT: When  
458 are Randomized Trials Unnecessary for New Therapeutic Devices, and What Should We  
459 Do Instead? *Ann. Surg.* 2021;275(2):324–331. Doi: 10.1097/SLA.0000000000005053.
- 460 17. Baggaley AE, Lafaurie GBRC, Tate SJ, et al. Pressurized intraperitoneal aerosol  
461 chemotherapy (PIPAC): updated systematic review using the IDEAL framework. *Br. J.  
462 Surg.* 2022;110(1):10–18. Doi: 10.1093/bjs/znac284.
- 463 18. Hoskovec D, Dytrych P, Vocka M, Krska Z, Skala R MCR-4 TOPOL® new device for  
464 PIPAC – first clinical use. *Eur. J. Surg. Oncol.* 2022;48(2):e155. Doi:  
465 10.1016/j.ejso.2021.12.308.
- 466 19. Rahimi-Gorji M, Debbaut C, Ghorbaniasl G, Cosyns S, Willaert W, Ceelen W Optimization  
467 of Intraperitoneal Aerosolized Drug Delivery: A Computational Fluid Dynamics (CFD) and  
468 Experimental Study. *Scientific Reports* 2021;12(1). Doi: 10.1038/s41598-022-10369-8.
- 469 20. Göhler D, Geldner A, Gritzki R, et al. Development of a rat capnoperitoneum phantom  
470 (RCP) to study drug aerosol deposition in the context of anticancer research on peritoneal  
471 carcinomatosis. *Sci. Rep.* 2021;11:21843. Doi: 10.1038/s41598-021-01332-0.

- 472 21. Göhler D, Große S, Bellendorf A, et al. Hyperthermic intracavitary nano-aerosol therapy  
473 (HINAT) as improved approach for pressurised intraperitoneal aerosol chemotherapy  
474 (PIPAC): Technical description, experimental validation and first proof of concept.  
475 Beilstein J. Nanotechnol. 2017;8:2729–2740. Doi: 10.3762/bjnano.8.272.
- 476 22. Buggisch JR, Göhler D, Sobilo J, et al. Development and technical validation of an  
477 ultrasound nebulizer to deliver intraperitoneal pressurized aerosols in a rat colon cancer  
478 peritoneal metastases model. BMC Cancer 2022;22(570). Doi: 10.1186/s12885-022-09668-  
479 0.
- 480 23. Rezniczek GA, Buggisch J, Sobilo J, et al. Establishment of a mouse ovarian cancer and  
481 peritoneal metastasis model to study intraperitoneal chemotherapy. Cancers 2020;12(12).  
482 Doi: 10.3390/cancers12123818.
- 483 24. Höltzcke P, Sautkin I, Clere S, Castagna A, Königsrainer A, Pott PP, Reymond MA.  
484 Feasibility of pressurized intra peritoneal aerosol chemotherapy using an ultrasound aerosol  
485 generator (usPIPAC). Surg Endosc. 2022 Oct;36(10):7848-7858. doi: 10.1007/s00464-022-  
486 09525-y. Epub 2022 Aug 29. PMID: 36038646; PMCID: PMC9485099.
- 487 25. Toussaint L, Sautkin Y, Illing B, Weinreich FJ, Nadiradze G, Königsrainer A, Wichmann  
488 D. Correction to: Comparison between microcatheter and nebulizer for generating  
489 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Surg Endosc. 2021  
490 Aug;35(8):4901. doi: 10.1007/s00464-021-08577-w. Erratum for: Surg Endosc. 2021  
491 Apr;35(4):1636-1643. PMID: 34106308; PMCID: PMC8263410.
- 492 26. Mun J, Park SJ, Kim HS. Rotational intraperitoneal pressurized aerosol chemotherapy in a  
493 porcine model. Gland Surg. 2021 Mar;10(3):1271-1275. doi: 10.21037/gs-2019-ursoc-11.  
494 PMID: 33842275; PMCID: PMC8033043.
- 495 27. Mimouni, M., Richard, C., Adenot, P. et al. Pressurized intra-peritoneal aerosol  
496 chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution  
497 patterns but leads to deeper penetration depth of doxorubicin in a sheep model. BMC Cancer  
498 21, 461 (2021). <https://doi.org/10.1186/s12885-021-07955-w>
- 499 28. Giger-Pabst, U., Bucur, P., Roger, S. et al. Comparison of Tissue and Blood Concentrations  
500 of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann  
501 Surg Oncol 26, 4445–4451 (2019). <https://doi.org/10.1245/s10434-019-07695-z>
- 502 29. Andrade C Bioequivalence of Generic Drugs: A Simple Explanation for a US Food and  
503 Drug Administration Requirement. Journal of Clinical Psychiatry 2015;76(06):e742–e744.  
504 Doi: 10.4088/JCP.15f10094.